{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-006444","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.606721+00:00","generated_at":"2026-05-16T03:01:49.378887+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Celcuity appoints Charles Romp to board of directors; brings commercial oncology expertise","bullets":["Charles (Chip) R. Romp appointed to board, effective Feb 11, 2026; board size increased from 7 to 8.","Romp is CEO of Secura Bio, previously EVP Commercial at Seagen (sold to Pfizer), with 25+ years oncology experience.","He will receive $50k annual cash retainer, $100k annual equity award, and pro-rated grant of 215 restricted shares vesting by 2026 annual meeting or April 30.","Company notes preparation for potential approval and launch of gedatolisib later this year (HR+/HER2- advanced breast cancer).","Romp qualifies as independent under Nasdaq and SEC rules; no committee assignments yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-006444","json":"https://secwatch.observer/filing/0001493152-26-006444.json","markdown":"https://secwatch.observer/filing/0001493152-26-006444.md","text":"https://secwatch.observer/filing/0001493152-26-006444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315226006444/0001493152-26-006444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315226006444/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:01:49.378887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}